Apollo Hospitals: Revenue Expansion, Bed Capacity, and Digital Turnaround

reported a 20.5% year-on-year rise in consolidated revenue to ₹7,043 crore for Q1FY27, with Ebitda margins expanding to 15.5%. Growth was driven by a 22% surge in healthcare services revenue, an increase in hospital occupancy to 70%, and higher average revenue per in-patient. Bed Capacity Pipeline: To drive long-term growth, the company commissioned five new hospitals, adding about 1,000 beds. Out of these, 380 beds are already operational, while 620 beds will be operationalized over 12–18 months. Total expansion expenditure is projected at ₹11,150 crore, with ₹7,500 crore remaining to be spent. FY27 Segment Guidance: Management targets an 18–20% revenue growth for the hospital segment in FY27, backed by 13–14% growth in established units and a 7% contribution from new capacity. Established units aim to maintain a 26% Ebitda margin, though initial launch costs in regions like Gurgaon will create a near-term drag of ₹150 crore. Apollo HealthCo Profitability: The HealthCo segment contributed 42% of consolidated revenue, growing 20% to ₹2,977 crore. Margins improved to 5.8% as losses at digital platform Apollo 24/7 dropped significantly to ₹10 crore due to strict operating cost controls. Digital Breakeven Timeline: Slower transactional volume growth pushed Apollo 24/7's digital cash breakeven to Q2FY27E, with full breakeven expected by Q3FY27E. The planned demerger of Apollo HealthCo remains a major upcoming catalyst for the stock. Positive Stock Outlook: Motilal Oswal Financial Securities maintains a 12-month target price of ₹10,160 based on sum-of-the-parts valuation, anticipating steady momentum from established facilities, bed rollouts, and digital cost efficiencies.